Abstract
High-precision measurements of flow coefficients
$$v_{n}$$
v
n
(
$$n = 1 - 4$$
n
=
1
-
4
) for protons, deuterons and tritons relative to the first-order spectator plane have been performed ...in Au+Au collisions at
$$\sqrt{s_{_{{\text {NN}}}= 2.4$$
s
NN
=
2.4
GeV with the High-Acceptance Di-Electron Spectrometer (HADES) at the SIS18/GSI. Flow coefficients are studied as a function of transverse momentum
$$p_{{\text {t}}}$$
p
t
and rapidity
$$y_{{\text {cm}}}$$
y
cm
over a large region of phase-space and for several classes of collision centrality. A clear mass hierarchy, as expected by relativistic hydrodynamics, is found for the slope of
$$v_{1}$$
v
1
,
$$d v_{1}/d y^{\prime }|_{y^{\prime } = 0}$$
d
v
1
/
d
y
′
|
y
′
=
0
where
$$y^{\prime }$$
y
′
is the scaled rapidity, and for
$$v_{2}$$
v
2
at mid-rapidity. Scaling with the number of nucleons is observed for the
$$p_{{\text {t}}}$$
p
t
dependence of
$$v_{2}$$
v
2
and
$$v_{4}$$
v
4
at mid-rapidity, which is indicative for nuclear coalescence as the main process responsible for light nuclei formation.
$$v_{2}$$
v
2
is found to scale with the initial eccentricity
$$\langle \epsilon _{2} \rangle $$
⟨
ϵ
2
⟩
, while
$$v_{4}$$
v
4
scales with
$$\langle \epsilon _{2} \rangle ^{2}$$
⟨
ϵ
2
⟩
2
and
$$\langle \epsilon _{4} \rangle $$
⟨
ϵ
4
⟩
. The multi-differential high-precision data on
$$v_{1}$$
v
1
,
$$v_{2}$$
v
2
,
$$v_{3}$$
v
3
, and
$$v_{4}$$
v
4
provides important constraints on the equation-of-state of compressed baryonic matter.
In nuclear collisions the incident protons generate a Coulomb field which acts on produced charged particles. The impact of these interactions on charged-pion transverse-mass and rapidity spectra, as ...well as on pion–pion momentum correlations is investigated in Au + Au collisions at
s
NN
= 2.4 GeV. We show that the low-
m
t
region (
m
t
<
0.2
GeV/
c
2
) can be well described with a Coulomb-modified Boltzmann distribution that also takes changes of the Coulomb field during the expansion of the fireball into account. The observed centrality dependence of the fitted mean Coulomb potential energy deviates strongly from a
A
part
2
/
3
scaling, indicating that, next to the fireball, the non-interacting charged spectators have to be taken into account. For the most central collisions, the Coulomb modifications of the HBT source radii are found to be consistent with the potential extracted from the single-pion transverse-mass distributions. This finding suggests that the region of homogeneity obtained from two-pion correlations coincides with the region in which the pions freeze-out. Using the inferred mean-square radius of the charge distribution at freeze-out, we have deduced a baryon density, in fair agreement with values obtained from statistical hadronization model fits to the particle yields.
Yttrium-90 ibritumomab tiuxetan (IDEC-Y2B8) is a murine immunoglobulin G1 kappa monoclonal antibody that covalently binds MX-DTPA (tiuxetan), which chelates the radioisotope yttrium-90. The antibody ...targets CD20, a B-lymphocyte antigen. A multicenter phase I/II trial was conducted to compare two doses of unlabeled rituximab given before radiolabeled antibody, to determine the maximum-tolerated single dose of IDEC-Y2B8 that could be administered without stem-cell support, and to evaluate safety and efficacy.
Eligible patients had relapsed or refractory (two prior regimens or anthracycline if low-grade disease) CD20(+) B-cell low-grade, intermediate-grade, or mantle-cell non-Hodgkin's lymphoma (NHL). There was no limit on bulky disease, and 59% had at least one mass > or = 5 cm.
The maximum-tolerated dose was 0.4 mCi/kg IDEC-Y2B8 (0.3 mCi/kg for patients with baseline platelet counts 100 to 149,000/microL). The overall response rate for the intent-to-treat population (n = 51) was 67% (26% complete response CR; 41% partial response PR); for low-grade disease (n = 34), 82% (26% CR; 56% PR); for intermediate-grade disease (n = 14), 43%; and for mantle-cell disease (n = 3), 0%. Responses occurred in patients with bulky disease (> or = 7 cm; 41%) and splenomegaly (50%). Kaplan-Meier estimate of time to disease progression in responders and duration of response is 12.9+ months and 11.7+ months, respectively. Adverse events were primarily hematologic and correlated with baseline extent of marrow involvement with NHL and baseline platelet count. One patient (2%) developed an anti-antibody response (human antichimeric antibody/human antimouse antibody).
These phase I/II data demonstrate that IDEC-Y2B8 radioimmunotherapy is a safe and effective alternative for outpatient therapy of patients with relapsed or refractory NHL. A phase III study is ongoing.
The purpose of this study was to investigate whether marrow radiation absorbed dose estimates predict haematotoxicity following radioimmunotherapy with an yttrium-90 labelled anti-CD20 monoclonal ...antibody in non-Hodgkinʼs B-cell lymphoma (NHL). Radiopharmaceutical data from 12 NHL radioimmunotherapy patients were analysed retrospectively using three methods of marrow radiation absorbed dose estimation based on serial pretreatment indium-111 labelled anti-CD20 monoclonal antibody activity versus time data (0-144 h)(i) lumbar spine (LS) image counts; (ii) blood clearance (BL); and (iii) whole body (WB) activity. Linear regressions were performed between the methods, and between each method and the 0-6 month post-treatment platelet and white blood cell count nadir and absolute drop in count (ADC). For the range of yttrium-90 activities (740-1547 MBq), absorbed dose estimates (mean±σ) wereLS, 142±50 cGy (range 62-233 cGy); BL, 89±21 cGy (range 63-140 cGy); and WB, 54±10 cGy (range 36-63 cGy). The LS and BL marrow estimates differed significantly (P<0.003), with a correlation coefficient r of 0.36 (P = NS), while WB correlated significantly with both LS (r = 0.50, P<0.05) and BL (r = 0.58, P<0.05). The range of r with platelet nadir and ADC was −0.20≤r≤0.01, except for WB with ADC (r = 0.38) (all P = NS). Values of r for white blood cell nadir were unexpectedly positive, being 0.13 for BL and 0.29 for LS (P = NS), and 0.60 for WB (P<0.025). Values of r for white blood cell ADC were 0.36 for BL and −0.26 for LS (P = NS), and 0.50 for WB (P<0.05). These results indicate that different commonly employed methods of estimating marrow radiation absorbed dose may yield significantly differing results, which may not correlate with actual radiation toxicity. Therefore, caution must be exercised in relying on these results to predict haematotoxicity.
Veitch et al suggest that sucrase malabsorption resulting in increased colonic short chain fatty acids in the black South African population might be one of a number of protective mechanisms against ...non-infectious colonic dis
Pantoprazole is a substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+, K+-ATPase.
Pantoprazole 40 mg and 80 mg were compared in a randomized ...double-blind study in 192 out-patients with stage II or III (Savary-Miller classification) reflux oesophagitis. Patients received either pantoprazole 40 mg (n = 97) or pantoprazole 80 mg (n = 95), once daily before breakfast for 4 weeks. Treatment was extended for a further 4 weeks if the oesophagitis had not healed.
After 4 weeks complete healing of the reflux oesophagitis was seen in 78% of protocol-correct patients given pantoprazole 40 mg daily (n = 86), and in 72% in the 80 mg (n = 87) group. The cumulative healing rates after 8 weeks were 95 and 94%, respectively (P > 0.05, Cochran-Mantel-Haenszel), and time until healing of oesophagitis comparable in both groups. Differences between doses were also not significant in an intention-to-treat analysis. Both dosing schedules were well tolerated and the patients experienced remarkable symptom relief. No adverse event or changes in laboratory values of clinical significance could definitely be ascribed to the trial medication.
The 40 mg pantoprazole dosage is comparable to 80 mg in reflux oesophagitis, both in efficacy and tolerability.
Mildly thrombocytopenic patients with relapsed or refractory low-grade non-Hodgkin lymphoma (NHL) have an increased risk of chemotherapy-induced myelosuppression following treatment. The safety and ...efficacy of radioimmunotherapy with a reduced dose of90Y ibritumomab tiuxetan (0.3 mCi/kg 11 MBq/kg; maximum 32 mCi 1.2 GBq) was evaluated in 30 patients with mild thrombocytopenia (100-149 × 109 platelets/L) who had advanced, relapsed or refractory, low-grade, follicular, or transformed B-cell NHL. The ibritumomab tiuxetan regimen included an infusion of rituximab (250 mg/m2) and injection of 111In ibritumomab tiuxetan (5 mCi 185 MBq) for dosimetry evaluation, followed 1 week later with rituximab (250 mg/m2) and90Y ibritumomab tiuxetan (0.3 mCi/kg 11 MBq/kg). Patients (median age, 61 years; 90% stage III/IV at study entry; 83% follicular lymphoma; and 67% with bone marrow involvement) had a median of 2 prior therapy regimens (range, 1-9). Estimated radiation-absorbed doses were well below the study-defined maximum allowable for all 30 patients. With the use of the International Workshop criteria for NHL response assessment, the overall response rate was 83% (37% complete response, 6.7% complete response unconfirmed, and 40% partial response). Kaplan-Meier estimated median time to progression (TTP) was 9.4 months (range, 1.7-24.6). In responders, Kaplan-Meier estimated median TTP was 12.6 months (range, 4.9-24.6), with 35% of data censored. Toxicity was primarily hematologic, transient, and reversible. The incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 33%, 13%, and 3%, respectively. Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has significant clinical activity in this patient population.
PDF
